Priority Date: 20.12.13 (EP 20130199138)

HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS

  • Application ID: EP14833234
  • Status: The patent has been granted

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
1 office
Technology Company

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Novartis Pharma AG is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 231 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 20.12.2013 - Priority Date (EP 20130199138)
  • 25.06.2015 - Publication A1 (WO2015092740)
  • 26.10.2016 - Publication A1 (EP3083564)
  • 11.07.2018 - Publication B1 (EP3083564)